{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:36:31Z","timestamp":1791596191096,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pelvic exenteration (PE) may be associated with prolonged overall survival (OS) in selected patients with advanced or recurrent cervical cancer. However, the factors related to improved survival following PE are not clearly defined. The aim of this study was to perform a retrospective analysis of OS rates in a group of patients undergoing PE in order to identify the factors related to improved long-term outcomes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Our study group consisted of 44 patients, including 21 squamous cell cancer (SCC) patients, 22 patients with adenocarcinomas (AC) of the cervix, and one patient with undifferentiated cervical carcinoma. The patients were categorized according to the type of surgery, namely, primary surgery (12 patients) or surgery due to cancer recurrence (32 patients).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the group of patients with recurrent cervical cancer, we found that improved OS correlated with the SCC histological type and the presence of vaginal fistula. The need for reoperation within 30\u2009days and the presence of severe adverse events significantly worsened the prognosis. We found a non significant trend toward improved survival in those patients with tumor-free margins. Lymph node metastases, the initial stage of the disease, the time to recurrence, and a history of hysterectomy had no impact on patients\u2019 OS. In the group of patients undergoing primary PE, we observed a trend toward improved survival among those diagnosed with vaginal fistula.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Pelvic exenteration seemed to improve the long-term outcomes for patients with SCC cancer recurrence and vaginal fistula whose surgery was unrelated to severe adverse events.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12957-020-01997-3","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T16:03:43Z","timestamp":1599062623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Agnieszka","family":"Lewandowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Szubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Koper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Koper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Cwynar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8575-0251","authenticated-orcid":false,"given":"Lukasz","family":"Wicherek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"1997_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/1097-0142(194807)1:2<177::AID-CNCR2820010203>3.0.CO;2-A","volume":"1","author":"A Brunschwig","year":"1948","unstructured":"Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. A one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948;1:177\u201383 10.1002\/1097-0142(194807)1:2<177::AID-CNCR2820010203>3.0.CO;2-A.","journal-title":"Cancer"},{"key":"1997_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00404-019-05154-4","volume":"300","author":"N de Gregorio","year":"2019","unstructured":"de Gregorio N, de Gregorio A, Ebner F, Friedl TWP, Huober J, Hefty R, Wittau M, Janni W, Widschwendter P. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Arch Gynecol Obstet. 2019;300:161\u20138. https:\/\/doi.org\/10.1007\/s00404-019-05154-4.","journal-title":"Arch Gynecol Obstet"},{"key":"1997_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.21873\/invivo.11723","volume":"33","author":"N Bacalbasa","year":"2019","unstructured":"Bacalbasa N, Balescu I, Vilcu M, Neacsu A, Dima S, Croitoru A, Brezean I. Pelvic exenteration for locally advanced and relapsed pelvic malignancies - an analysis of 100 cases. In Vivo. 2019;33:2205\u201310. https:\/\/doi.org\/10.21873\/invivo.11723.","journal-title":"In Vivo"},{"key":"1997_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/SLA.0b013e31828a0d22","volume":"259","author":"A Bhangu","year":"2014","unstructured":"Bhangu A, Ali SM, Brown G, Nicholls RJ, Tekkis P. Indications and outcome of pelvic exenteration for locally advanced primary and recurrent rectal cancer. Ann Surg. 2014;259:315\u201322. https:\/\/doi.org\/10.1097\/SLA.0b013e31828a0d22.","journal-title":"Ann Surg"},{"key":"1997_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s10350-006-0651-x","volume":"49","author":"FTJ Ferenschild","year":"2006","unstructured":"Ferenschild FTJ, Vermaas M, Nuyttens JJME, Graveland WJ, Marinelli AWKS, van der Sijp JR, Wiggers T, Verhoef C, Eggermont AMM, de Wilt JHW. Value of intraoperative radiotherapy in locally advanced rectal cancer. Dis Colon Rectum. 2006;49:1257\u201365. https:\/\/doi.org\/10.1007\/s10350-006-0651-x.","journal-title":"Dis Colon Rectum"},{"key":"1997_CR6","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s00268-010-0637-7","volume":"34","author":"E Zoucas","year":"2010","unstructured":"Zoucas E, Frederiksen S, Lydrup M-L, M\u00e5nsson W, Gustafson P, Alberius P. Pelvic exenteration for advanced and recurrent malignancy. World J Surg. 2010;34:2177\u201384. https:\/\/doi.org\/10.1007\/s00268-010-0637-7.","journal-title":"World J Surg"},{"key":"1997_CR7","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.4103\/0366-6999.235111","volume":"131","author":"L Li","year":"2018","unstructured":"Li L, Ma S-Q, Tan X-J, Zhong S, Wu M. Pelvic exenteration for recurrent and persistent cervical cancer. Chin Med J. 2018;131:1541\u20138. https:\/\/doi.org\/10.4103\/0366-6999.235111.","journal-title":"Chin Med J"},{"key":"1997_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/bf02258294","volume":"43","author":"C R\u00f6del","year":"2000","unstructured":"R\u00f6del C, Grabenbauer GG, Matzel KE, Schick C, Fietkau R, Papadopoulos T, Martus P, Hohenberger W, Sauer R. Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum. 2000;43:312\u20139. https:\/\/doi.org\/10.1007\/bf02258294.","journal-title":"Dis Colon Rectum"},{"key":"1997_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11912-014-0435-8","volume":"17","author":"M H\u00f6ckel","year":"2015","unstructured":"H\u00f6ckel M. Long-term experience with (laterally) extended endopelvic resection (LEER) in relapsed pelvic malignancies. Curr Oncol Rep. 2015;17:435. https:\/\/doi.org\/10.1007\/s11912-014-0435-8.","journal-title":"Curr Oncol Rep"},{"key":"1997_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/SLA.0000000000003533","volume":"270","author":"PelvExCollaborative","year":"2019","unstructured":"PelvExCollaborative. Pelvic exenteration for advanced nonrectal pelvic malignancy. Ann Surg. 2019;270:899\u2013905. https:\/\/doi.org\/10.1097\/SLA.0000000000003533.","journal-title":"Ann Surg"},{"key":"1997_CR11","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3802\/jgo.2018.29.e68","volume":"29","author":"RJ Jalloul","year":"2018","unstructured":"Jalloul RJ, Nick AM, Munsell MF, Westin SN, Ramirez PT, Frumovitz M, Soliman PT. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. J Gynecol Oncol. 2018;29:e68. https:\/\/doi.org\/10.3802\/jgo.2018.29.e68.","journal-title":"J Gynecol Oncol"},{"key":"1997_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1470-2045(06)70903-2","volume":"7","author":"M H\u00f6ckel","year":"2006","unstructured":"H\u00f6ckel M, Dornh\u00f6fer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006;7:837\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(06)70903-2.","journal-title":"Lancet Oncol"},{"key":"1997_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ygyno.2019.02.002","volume":"153","author":"K Matsuo","year":"2019","unstructured":"Matsuo K, Mandelbaum RS, Adams CL, Roman LD, Wright JD. Performance and outcome of pelvic exenteration for gynecologic malignancies: a population-based study. Gynecol Oncol. 2019;153:368\u201375. https:\/\/doi.org\/10.1016\/j.ygyno.2019.02.002.","journal-title":"Gynecol Oncol"},{"key":"1997_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/IGC.0000000000000884","volume":"27","author":"S Graves","year":"2017","unstructured":"Graves S, Seagle B-LL, Strohl AE, Shahabi S, Nieves-Neira W. Survival after pelvic exenteration for cervical cancer: a national cancer database study. Int J Gynecol Cancer. 2017;27:390\u20135. https:\/\/doi.org\/10.1097\/IGC.0000000000000884.","journal-title":"Int J Gynecol Cancer"},{"key":"1997_CR15","doi-asserted-by":"publisher","unstructured":"Schmidt AM, Imesch P, Fink D, Egger H. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecol Oncol. 2012:604\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2012.03.001.","DOI":"10.1016\/j.ygyno.2012.03.001"},{"key":"1997_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s13193-018-0792-0","volume":"9","author":"I Karmaniolou","year":"2018","unstructured":"Karmaniolou I, Arkadopoulos N, Vassiliou P, Nastos C, Dellaportas D, Siatelis A, Theodosopoulos T, Vezakis A, Parasyris S, Polydorou A, Smyrniotis V. Pelvic exenteration put into therapeutical and palliative perspective: it is worth to try. Indian J Surg Oncol. 2018;9:552\u20137. https:\/\/doi.org\/10.1007\/s13193-018-0792-0.","journal-title":"Indian J Surg Oncol"},{"key":"1997_CR17","doi-asserted-by":"publisher","unstructured":"Murphy C, Rettedal E, Lehouritis P, Devoy C, Tangney M. Intratumoural production of TNF\u03b1 by bacteria mediates cancer therapy. PLoS One. 2017;12. https:\/\/doi.org\/10.1371\/journal.pone.0180034.","DOI":"10.1371\/journal.pone.0180034"},{"key":"1997_CR18","doi-asserted-by":"publisher","unstructured":"Ungar L, Palfalvi L, Novak Z. Primary pelvic exenteration in cervical cancer patients. Gynecol Oncol. 2008;111. https:\/\/doi.org\/10.1016\/j.ygyno.2008.07.041.","DOI":"10.1016\/j.ygyno.2008.07.041"},{"key":"1997_CR19","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"C Vale","year":"2008","unstructured":"Vale C, Tierney JF, Stewart LA, Brady M, Dinshaw K, Jakobsen A, Parmar MKB, Thomas G, Trimble T, Alberts DS, Chen H, Cikaric S, Eifel PJ, Garipagaoglu M, Keys H, Kantardzic N, Lal P, Lanciano R, Leborgne F, Lorvidhaya V, Onishi H, Pearcey RG, Pras E, Roberts K, Rose PG, Whitney CW. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802\u201312. https:\/\/doi.org\/10.1200\/JCO.2008.16.4368.","journal-title":"J Clin Oncol"},{"key":"1997_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ygyno.2011.02.024","volume":"121","author":"PG Rose","year":"2011","unstructured":"Rose PG, Ali S, Whitney CW, Lanciano R, Stehman FB. Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a gynecologic oncology group study. Gynecol Oncol. 2011;121:542\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2011.02.024.","journal-title":"Gynecol Oncol"},{"key":"1997_CR21","doi-asserted-by":"publisher","first-page":"112855","DOI":"10.18632\/oncotarget.22836","volume":"8","author":"M Hata","year":"2017","unstructured":"Hata M, Koike I, Miyagi E, Numazaki R, Asai-Sato M, Kaizu H, Mukai Y, Takano S, Ito E, Sugiura M, Inoue T. Radiation therapy for stage IVA uterine cervical cancer: treatment outcomes including prognostic factors and risk of vesicovaginal and rectovaginal fistulas. Oncotarget. 2017;8:112855\u201366. https:\/\/doi.org\/10.18632\/oncotarget.22836.","journal-title":"Oncotarget"},{"key":"1997_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/IGC.0b013e3182a80aec","volume":"24","author":"V Chiantera","year":"2014","unstructured":"Chiantera V, Rossi M, De Iaco P, Koehler C, Marnitz S, Ferrandina G, Legge F, Parazzini F, Scambia G, Schneider A, Vercellino GF. Survival after curative pelvic exenteration for primary or recurrent cervical cancer a retrospective multicentric study of 167 patients. Int J Gynecol Cancer. 2014;24:916\u201322. https:\/\/doi.org\/10.1097\/IGC.0b013e3182a80aec.","journal-title":"Int J Gynecol Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-01997-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:30:12Z","timestamp":1630539012000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-01997-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1997"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-01997-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"9 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study received the Center of Postgraduate Medical Education Ethical Committee approval (7\/PB\/2020).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL, SSz, KK, AK, GC, and LW have no conflicts of interest or financial ties to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"234"}}